‘Quite significant’: Tilray wins approval to export cannabis formulation to U.S. for clinical trial

TORONTO — Canadian licensed marijuana producer Tilray Inc. has received the green light from the U.S. Drug Enforcement Administration agency to export a medical cannabis product south of the border for use in a clinical trial.

The Nanaimo, B.C.-based company and a researcher at the University of California San Diego believe it is the first export of a cannabis study drug from a Canadian company to the U.S., where marijuana is still illegal at the federal level.

Tilray will be exporting capsules containing a cannabinoid formulation with the active ingredients cannabidiol and tetrahydrocannabinol, better known as CBD and THC, for a study examining the drug as a potential treatment for adults with essential tremor.